AGREEMENT FOR THE COLLABORATION BETWEEN CELLTECH R & D LTD and UCB FARCHIM S.A. *CONFIDENTIAL MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION.Celltech Group PLC • July 8th, 2004 • Pharmaceutical preparations • England
Scope Collaboration between Celltech and UCB, on a co-exclusive basis (“Co-exclusive” meaning UCB and Celltech only and limited to their respective rights hereunder), for the further development, manufacture and commercialisation of the Product initially for the treatment of rheumatoid arthritis (‘RA’) and Crohn’s disease in humans and for the treatment of any other agreed indications in the Field. The co-exclusive collaboration includes the right to appoint any third party including but not limited to affiliated companies as distributors, except for Japan where UCB shall have the right to appoint sub-licensees.
ORPHAN MEDICAL INC. AND CELLTECH PHARMACEUTICALS LTD. XYREM® LICENSE AND DISTRIBUTION AGREEMENTLicense and Distribution Agreement • June 25th, 2004 • Celltech Group PLC • Pharmaceutical preparations • New York
This LICENSE AND DISTRIBUTION AGREEMENT (this “Agreement”) is made and entered into as of October 29, 2003 (“Effective Date”), by and between Orphan Medical, Inc., a corporation having its principal place of business at 13911 Ridgedale Drive, Suite 250, Minnetonka, Minnesota 55305, USA (together with its Affiliates, “Orphan Medical”), and Celltech Pharmaceuticals, Ltd., a biopharmaceutical company organized under the laws of England having its principal place of business at 208 Bath Road, Slough, Berkshire SL1 3WE, United Kingdom (together with its Affiliates, “Celltech”).
DATE 16 April 2003 SERVICE AGREEMENT BETWEEN CELLTECH GROUP PLC (the “Company”) And DR GORAN ANDO (the “Executive”) ALLEN & OVERYService Agreement • June 14th, 2004 • Celltech Group PLC • Pharmaceutical preparations
DATED 11TH MAY 1992 MR. PETER V. ALLEN - and - CELLTECH LIMITED TERMS AND CONDITIONS OF EMPLOYMENTAgreement • June 14th, 2004 • Celltech Group PLC • Pharmaceutical preparations
AGREEMENT is made the 24th day of September 1998 BETWEENAgreement • June 14th, 2004 • Celltech Group PLC • Pharmaceutical preparations
ContractCelltech Group PLC • June 25th, 2004 • Pharmaceutical preparations • England
*CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN *.
ContractAgreement • June 30th, 2003 • Celltech Group PLC • Pharmaceutical preparations
*CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN *.
AGREEMENT DATED 18th December, 2002 REVOLVING CREDIT FACILITY for CELLTECH GROUP PLC arranged by THE ROYAL BANK OF SCOTLAND PLC ALLEN & OVERY London ALLEN & OVERY LondonAgreement • June 30th, 2003 • Celltech Group PLC • Pharmaceutical preparations • Delaware
AGREEMENT FOR THE COLLABORATION BETWEEN CELLTECH R & D LTD and UCB FARCHIM S.A. *CONFIDENTIAL MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION.Celltech Group PLC • June 14th, 2004 • Pharmaceutical preparations • England
Scope Collaboration between Celltech and UCB, on a co-exclusive basis (“Co-exclusive” meaning UCB and Celltech only and limited to their respective rights hereunder), for the further development, manufacture and commercialisation of the Product initially for the treatment of rheumatoid arthritis (‘RA’) and Crohn’s disease in humans and for the treatment of any other agreed indications in the Field. The co-exclusive collaboration includes the right to appoint any third party including but not limited to affiliated companies as distributors, except for Japan where UCB shall have the right to appoint sub-licensees.
OPTION AGREEMENT between PHARMACIA AB and CELLTECH PHARMACEUTICALS LTD. Dated as of July 23, 2002Option Agreement • June 30th, 2003 • Celltech Group PLC • Pharmaceutical preparations • New York
This OPTION AGREEMENT (the “Option Agreement”) is entered into as of July 23, 2002 by and between Pharmacia AB, a Swedish corporation, (“Pharmacia”) and Celltech Pharmaceuticals Ltd., an English corporation (“Celltech”).
AMENDMENT TO OPTION AGREEMENT AND AGREEMENTOption Agreement • June 25th, 2004 • Celltech Group PLC • Pharmaceutical preparations
This Amendment (this “Amendment”) to Option Agreement, dated July 23, 2002, between the parties hereto (the “Option Agreement”) and the Agreement, dated July 23, 2002, between the parties hereto (the “License Agreement”) is made as of April 15, 2004 (the “Date of this Amendment”) by and between Pfizer Health AB (formerly Pharmacia AB), a corporation organized and existing under the laws of Sweden (“Pfizer”), and Celltech Pharmaceuticals Ltd., a corporation organized and existing under the laws of England (“Celltech”).
CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN *. AGREEMENT BETWEEN PHARMACIA AB AND CELLTECH PHARMACEUTICALS LTD. DATED July 23, 2002Agreement • June 30th, 2003 • Celltech Group PLC • Pharmaceutical preparations • New York
This Agreement (the “Agreement”) is entered into as of July 23, 2002 (the “Effective Date”), by Pharmacia AB, a Swedish corporation (“Pharmacia”) and Celltech Pharmaceuticals Ltd., an English corporation (“Celltech”).
THIS AGREEMENT is made the day of 2002 BETWEEN:Agreement • June 30th, 2003 • Celltech Group PLC • Pharmaceutical preparations • London
COLLABORATION AND LICENSE AGREEMENT By and Between PHARMACIA & UPJOHN COMPANY and CELLTECH CHIROSCIENCE LIMITEDCollaboration and License Agreement • June 30th, 2003 • Celltech Group PLC • Pharmaceutical preparations • London
This Collaboration and License Agreement dated the 28th day of February, 2001 (the “Execution Date”) is by and between Pharmacia & Upjohn Company, a corporation organized and existing under the laws of the State of Delaware, USA and having a place of business at 100 Route 206 North, Peapack, New Jersey 07977 USA (“Pharmacia”), and Celltech Chiroscience Limited, a corporation organized and existing under the laws of England and having its principal office at 216 Bath Road, Slough, Berkshire SL1 4EN UK (“Celltech”).
MANUFACTURING SERVICES AGREEMENT dated: June 30, 2003 between CELLTECH R&D LIMITED and LONZA LIMITEDManufacturing Services Agreement • June 25th, 2004 • Celltech Group PLC • Pharmaceutical preparations
EUROPE ASSET PURCHASE AGREEMENT BETWEEN PHARMACIA AB AND CELLTECH PHARMACEUTICALS LTD. DATED AS OF SEPTEMBER 2, 2002Europe Asset Purchase Agreement • June 30th, 2003 • Celltech Group PLC • Pharmaceutical preparations • New York
This Europe Asset Purchase Agreement (the “Agreement”) is entered into as of September 2, 2002 (the “Effective Date”), by Pharmacia AB, a Swedish corporation (“Pharmacia”) and Celltech Pharmaceuticals Ltd., an English corporation (“Celltech”).
